Coenzyme Q10 and statins: Biochemical and clinical implications

Mitochondrion

Volumn 7, Issue SUPPL., 2007, Pages

  Littarru, Gian Paolo ^a   Langsjoen, Peter ^b  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b EAST TEXAS MEDICAL CENTER   (United States)

Author keywords

Coenzyme Q10; Hyperlipidemia; Statin side effects; Statins

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CREATINE KINASE; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PLACEBO; PRAVASTATIN; SIMVASTATIN; UBIDECARENONE; UBIQUINONE; DRUG DERIVATIVE; VITAMIN;

ARTICLE; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CREATINE KINASE BLOOD LEVEL; DIET SUPPLEMENTATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG WITHDRAWAL; ENZYME INHIBITION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; MONOTHERAPY; MORTALITY; MUSCLE FATIGUE; MUSCLE WEAKNESS; MUSCULOSKELETAL DISEASE; MYALGIA; MYOPATHY; NONHUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; SIDE EFFECT; TREATMENT DURATION; ANIMAL; BIOCHEMISTRY; BIOLOGICAL MODEL; BIOSYNTHESIS; COENZYME; DOG; HAMSTER; HEART DISEASE; METABOLISM; METHODOLOGY; PHYSIOLOGY; RAT; REVIEW;

ANIMALS; BIOCHEMISTRY; BIOSYNTHETIC PATHWAYS; CLINICAL TRIALS; COENZYMES; CRICETINAE; DOGS; HEART DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MODELS, BIOLOGICAL; RATS; UBIQUINONE; VITAMINS;

EID: 34248170185     PISSN: 15677249     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mito.2007.03.002     Document Type: Article

References (61)

1. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., Kirby A., Sourjina T., Peto R., Collins R., and Simes R. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 36 (2005) 1267-1278
2. Barbiroli B., Iotti S., and Lodi R. Improved brain and muscle mitochondrial respiration with CoQ. An in vivo study by 31P-MR spectroscopy in patients with mitochondrial cytopathies. Biofactors 9 (1999) 253-260
3. 10 supplementation prevents plasma ubiquinone reduction induced by HMG-CoA reductase inhibitors. Molecular Aspects of Medicine 15 (1994) 187-193
4. Belichard P., Pruneau D., and Zhiri A. Effect of a long-term treatment with lovastatin or fenofibrate on hepatic and cardiac ubiquinone levels in cardiomyopathic hamster. Biochimica Biophysica Acta 1169 (1993) 98-102
5. 10 levels in plasma. Drug Safety 29 (2006) 703-712
6. 10. American Heart Journal 142 (2001) E2
7. Caliskan S., Caliskan M., Kuralay F., and Onvural B. Effect of simvastatin therapy on blood and tissue ATP levels and erythrocyte membrane lipid composition. Research in Experimental Medicine 199 (2000) 189-194
8. Chariot P., Abadia R., Agnus D., Danan C., Charpentier C., and Gherardi R.K. Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome. The American Journal of Medicine 94 (1993) 109-110
9. 10 levels and left ventricular function in humans. European Journal of Clinical Investigation 35 (2005) 251-258
10. 10. Encyclopedia of Dietary Supplements (2005) 121-131
11. De Lorgeril M., Salen P., Bontemps L., Belichard P., Geyssant A., and Itti R. Effects of lipid-lowering drugs on left ventricular function and exercise tolerance in dyslipidemic coronary patients. Journal of Cardiovascular Pharmacology 33 (1999) 473-478
12. De Pinieux G., Chariot P., Ammi-Said M., Louarn F., Lejone J.L., Astier A., Jactot B., and Gherardi R. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. British Journal of Clinical Pharmacology 42 (1996) 333-337
13. Diebold B.A., Bhagavan N.V., and Guillory R.J. Influences of lovastatin administration on the respiratory burst of leukocyctes and the phosphorylation potential of mitochondria in guinea pigs. Biochimica Biophysica Acta 1200 (1994) 100-108
14. Folkers K., Langsjoen P., Willis R., Richardson P., Xia L.J., Ye C.Q., and Tamagawa H. Lovastatin decreases coenzyme Q levels in humans. Proceedings of the National Academy of Sciences USA 87 (1990) 8931-8934
15. Fukami M., Maeda N., Fukushige J., Kogure Y., Shimada Y., Ogawa T., and Tsujita Y. Effects of HMG-CoA reductase inhibitors on skeletal muscles of rabbits. Research in Experimental Medicine 193 (1993) 263-273
16. 10-lowering effect by HMG-CoA reductase inhibitors: a double blind, placebo-controlled study. Journal of Clinical Pharmacology 3 (1993) 226-229
17. Human J.A., Ubbink J.B., Jerling J.J., Gelport R., Varmaak W.J., Vorster H.H., Lagendijk J., and Potgieter H.C. The effect of Simvastatin on the plasma antioxidant concentrations in patients with hypercholesterolaemia. Clinica Chimica Acta 263 (1997) 67-77
18. Ichihara K., Satoh K., Yamamoto A., and Hoshi K. Are all HMG-CoA reductase inhibitors protective against ischemic heart disease?. Nippon Yakurigaku Zasshi 114 (1999) 142-149
19. Jackevicius C.A., Mamdani M., and Tu J.V. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. Journal of the American Medical Association 288 (2002) 462-467
20. Jula A., Marniemi J., Risto H., Virtanen A., and Ronnemaa T. Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men. A randomized controlled trial. Journal of the American Medical Association 287 (2002) 598-605
21. 10 in humans. FEBS Letters 443 (1999) 163-166
22. Kalen A., Appelkvist E.L., and Dallner G. Age-related changes in the lipid compositions of rat and human tissue. Lipids 24 (1989) 579-584
23. Kim W.S., Kim M.M., Choi H.J., Yoon S.S., Lee M.H., Park K., Park C.H., and Kang W.K. Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma. Investigational New Drugs 19 (2001) 81-83
24. Koumis T., Nathan J.P., Rosenberg J.M., and Cicero L.A. Strategies for the prevention and treatment of statin-induced myopahty: is there a role for ubiquinone supplementation?. American Journal of Health-System Pharmacists 61 (2004) 515-519
25. Laaksonen R., Jokelainen K., Laakso J., Sahi T., Harkonen M., Tikkanen M.J., and Himberg J.J. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. American Journal of Cardiology 77 (1996) 851-854
26. Laaksonen R., Jokelainen K., Sahi T., Tikkanen M.J., and Himberg J.J. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clinical Pharmacology and Therapeutics 57 (1995) 62-66
27. 10 level in statin-related myopathy. Archives of Neurology 62 (2005) 1709-1712
28. 10 and statin drug discontinuation. BioFactors 25 (2006) 147-152
29. Lees R.S., and Lees A.M. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. New England Journal of Medicine 333 (1995) 664-665
30. 10: an update. Clinical Nutrition and Metabolic Care 8 (2005) 641-646
31. 10 treatment on antioxidants and TBA reactive material in liver of rats. Molecular Aspects of Medicine 15 (1994) 195-206
32. Low P., Andersson M., Edlund C., and Dallner G. Effects of mevinolin treatment on tissue dolichol and ubiquionone levels in the rat. Biochimica Biophysica Acta 1165 (1992) 102-109
33. Mabuchi H., Higashikata T., Kawashiri M., Katsuda S., Mizuno M., Nohara A., Inazu A., Koizumi J., and Kobayashi J. Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients. Journal of Atherosclerosis Thrombosis 12 (2005) 111-119
34. Marz W., Siekmeier R., Muller H.M., Wieland H., Gross W., and Olbrich H.G. Effects of lovastatin and pravastatin on the survival of hamsters with inherited cardiomyopathy. Journal of Cardiovascular Pharmacology and Therapeutics 5 (2000) 275-279
35. 10 in diabetic patients. Arzneimittelforschung (1999) 324-329
36. 10 in 31P-NMR detected skeletal muscle energy metabolism in middle-aged post-polio subjects and normal volunteers. Molecular Aspects of Medicine 18 (1997) 291-298
37. Morand O.H., Aebi J.D., Dehmlow H., Ji Y.H., Gains N., Lengsfeld H., and Himber J.F. Ro 48-8.071, a new 2,3-oxidosqualene: lanosterol cyclase inhibitor lowering plasma cholesterol in hamsters, squirrel monkeys, and minipigs: comparison to simvastatin. Journal of Lipid Research 38 (1997) 373-390
38. 10 during treatment with HMG-CoA reductase inhibitors. Molecular Aspects of Medicine 18 (1997) 137-144
39. Nakahara K., Kuriyama M., Sonoda Y., Yoshidome H., Nakagawa H., Fujiyama J., Higuchi I., and Osame M. Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological, electrophysiological, and biochemical study. Toxicology and Applied Pharmacology 152 (1998) 99-106
40. 10 therapy for a mitochondrial encephalomyopathy with cytochrome c oxidase deficiency: a 31P NMR study. Neurology 39 (1989) 399-403
41. Paiva H., Thelen K.M., Van Coster R., Smet J., De Paepe B., Mattila K.M., Laakso J., Lehtimaki T., von Bergmann K., Lutjohann D., and Laaksonen R. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clinical Pharmacology Therapy 78 (2005) 60-68
42. Palomaki A., Malminiemi K., and Metsa-Ketela T. Enhanced oxidizability of ubiquinol and alpha-tocopherol during lovastatin treatment. FEBS Letters 410 (1997) 254-258
43. Palomaki A., Malminiemi K., Solakivi T., and Malminiemi O. Ubiquinone supplementation during lovastatin treatment: effect on LDL oxidation ex vivo. Journal of Lipid Research 39 (1998) 1430-1437
44. Passi S., Stancato A., Aleo E., Dmitrieva A., and Littarru G.P. Statins lower plasma and lymphocyte ubiquinol/ubiquinone without affecting other antioxidants and PUFA. BioFactors 18 (2003) 113-124
45. Pisarenko O.I., Studneva I.M., Lankin V.Z., Konovalova G.G., Tikhaze A.K., Kaminnaya V.I., and Belenkov Y.N. Inhibitor of beta-hydroxy-beta-methylglutaryl coenzyme A reductase decreases energy supply to the myocardium in rats. Bulletin of Experimental Biology and Medicine 132 (2001) 956-958
46. 10 level in the blood of patients at risk for cardiovascular disease and stroke. Archives of Neurology 61 (2004) 889-892
47. Satoh K., and Ichihara K. Lipophilic HMG-CoA reductase inhibitors increase myocardial stunning in dogs. Journal of Cardiovascular Pharmacology 35 (2000) 256-262
48. Satoh K., Yamato A., Nakai T., Hoshi K., and Ichihara K. Effects of 3-hydroxy-3-methylgltaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischaemic dog hearts. British Journal of Pharmacology 116 (1995) 1894-1898
49. Schaefer W.H., Lawrence J.W., Laughlin A.F., Stoffregen D.A., Mixson L.A., Dean D.C., Raab C.E., Yu NX., Lankas G.R., and Frederick C.B. Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats. Toxicology and Applied Pharmacology 194 (2004) 10-23
50. 10 to reverse that dysfunction. American Journal of Cardiology 94 (2004) 1306-1310
51. Soderberg M., Edlund C., Kristensson K., and Dallner G. Lipid composition of different regions of the human brain during aging. Journal of Neurochemistry 2 (1990) 415-423
52. 10 concentration, nor its decline during pravastatin therapy, is linked to recurrent cardiovascular disease events: A prospective case-control study from the LIPID study. Atherosclerosis 187 (2006) 198-204
53. Sugiyama S. HMG CoA reductase inhibitor accelerates aging effect on diaphragm mitochondrial respiratory function in rats. Biochemical and Molecular Biology International 46 (1998) 923-931
54. Thibault A., Samid D., Tompkins A.C., Figg W.D., Cooper M.R., Hohl R.J., Trepel J., Liang B., Patronas N., Venzon D.J., Reed E., and Myers C.E. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clinical Cancer Research 2 (1996) 483-491
55. Thompson P.D., Clarkson P., and Karas R.H. Statin-associated myopathy. Journal of the American Medical Association 289 (2003) 1681-1690
56. 10 ratio as a possible marker of increased risk for atherosclerosis. BioFactors 9 (1999) 231-240
57. 10 and maintains muscle damage after discontinuation of statin treatment. JAGS 54 (2006) 718-720
58. Walravens P.A., Greene C., and Frerman F.E. Lovastatin, isoprenes, and myopathy. Lancet 2 (1989) 1097-1098
59. Watts G.F., Castelluccio C., Rice Evans C., Taub N.A., Baum H., and Quinn P.J. Plasma coenzyme Q (ubiquinone) concentration in patients treated with simvastatin. Journal of Clinical Pathology 46 (1993) 1055-1057
60. Willis R.A., Folkers K., Tucker J.L., Ye C.Q., Xia L.J., and Tamagawa H. Lovastatin decreases coenzyme Q levels in rats. Procedures of the National Academy of Science USA 87 (1990) 8928-8930
61. Wong B., Lumma W.C., Smith A.M., Sisko J.T., Wright S.D., and Cai T.Q. Statins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylation. Journal of Leukocyte Biology 69 (2001) 959-962